Europe Digital PCR Market to Grow with a CAGR of 14.91% through 2030
Growing
adoption of digital PCR in clinical diagnostics and expanding application scope
in precision medicine, is expected to drive the Europe Digital PCR Market
growth in the forecast period, 2026-2030
According to
TechSci Research report, “Europe Digital PCR Market – By Country, Competition, Forecast & Opportunities, 2030F”, the Europe Digital PCR
Market was valued at USD 179.35
Million in 2024 and is expected to reach USD 413.45 Million by
2030 with a CAGR of 14.91%.
The Europe Digital PCR Market is evolving with growing emphasis on molecular
diagnostics and the demand for more precise quantification methods in research
and healthcare. Rising incidence of infectious diseases, antibiotic resistance,
and genetic disorders has prompted the need for tools that can offer
high-resolution genetic analysis. Digital PCR has emerged as a key solution due
to its ability to detect low-frequency mutations and perform absolute
quantification without relying on calibration curves. The method is being
increasingly applied in public health laboratories, pharma R&D, and
forensic science due to its enhanced reproducibility and sensitivity.
Diagnostic advancements in diseases like cancer and tuberculosis are propelling
the integration of dPCR into routine workflows across private and public
healthcare sectors.
The
market is also being shaped by strategic partnerships between diagnostic
companies and research institutions. These collaborations are helping to
develop disease-specific assays, multiplexing capabilities, and portable dPCR
instruments tailored for field diagnostics. The rise in demand for
decentralized testing, especially in remote or resource-limited environments,
is pushing companies to design compact and user-friendly dPCR devices. Growing
focus on environmental genomics, including wastewater-based epidemiology and
pathogen surveillance, is contributing to the increasing demand for precise
quantification methods offered by digital PCR. The application of dPCR in food
safety and GMO detection is another emerging trend that supports market
diversification.
The
Europe digital PCR market holds strong growth opportunities driven by the rise
of precision medicine and targeted therapy development. Pharmaceutical
companies are increasingly adopting digital PCR for pharmacokinetic and
biomarker studies to ensure tailored treatment approaches. There is growing
scope for the technology in veterinary diagnostics, agricultural genomics, and
biomanufacturing quality control. As digital PCR instruments become more
cost-efficient and integrated with AI-driven data analytics, the barriers to
entry are expected to reduce. Continuous expansion of molecular diagnostic
infrastructure in European countries, along with supportive regulatory
initiatives, is expected to unlock new avenues for adoption across clinical and
non-clinical applications.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Europe Digital PCR Market”
The Europe
Digital PCR Market is segmented into type, product, indication, end user, country
distribution, and company.
Based on the Type,
Chip-based Digital PCR emerged as the fastest growing segment in the Europe
Digital PCR Market during the forecast period. This is driven by the growing demand for
high-throughput, efficient, and cost-effective genetic testing solutions.
Chip-based digital PCR leverages microfluidic chips to conduct PCR reactions in
a parallel and automated manner, enabling faster analysis and reducing the
amount of reagents and sample volumes required. This innovation provides a high
level of sensitivity and precision in detecting low-abundance targets, making
it ideal for applications in disease diagnostics, genetic analysis, and
biomarker discovery. The key advantage of chip-based digital PCR is its ability
to perform high-throughput testing while minimizing the time and resources
required for analysis. These chips are designed for easy integration into
laboratory workflows, offering greater convenience for researchers and
clinicians. Furthermore, they are highly scalable, which supports the
increasing demand for large-scale genetic testing, particularly in research
settings and clinical laboratories focused on personalized medicine.
Based
on the Country, United Kingdom emerged as the fastest growing country in the Europe
Digital PCR Market during
the forecast period. This is due to the rapid adoption of advanced molecular
diagnostic technologies and the country’s strong emphasis on precision
medicine. The UK’s healthcare sector has witnessed significant investments in
research and development, particularly in genetic testing, cancer diagnostics,
and infectious disease detection. This has propelled the demand for digital
PCR, as it offers high sensitivity and accuracy, essential for detecting
low-abundance targets. The increasing focus on personalized medicine is a major
factor driving the growth of digital PCR in the UK. With personalized
treatments becoming more common, the need for precise molecular diagnostics has
risen. The UK government’s investment in genomics research, along with
initiatives such as the 100,000 Genomes Project, has provided a strong
foundation for the adoption of advanced technologies like digital PCR.
Major
companies operating in Europe Digital PCR Market are:
- QIAGEN
N.V.
- Stilla
Technologies
- Thermo
Fisher Scientific
- Merck
KGaA
- F.
Hoffmann-La Roche AG
- Bio-Rad
Laboratories
- Takara
Bio Europe AB
- Becton
Dickinson GmbH
- Abbott
Laboratories GmbH
- BIOMÉRIEUX
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Europe Digital PCR Market is
expanding due to the increasing integration of digital PCR technology in
clinical laboratories for oncology research. Digital PCR offers the advantage
of detecting rare mutations and monitoring minimal residual disease with higher
precision, making it a crucial tool for cancer diagnostics and monitoring. The
demand for highly accurate molecular diagnostics to assess tumor progression
and guide treatment decisions is driving the adoption of digital PCR platforms
in oncology. As more clinical studies and trials confirm the effectiveness of
digital PCR in cancer research, its use in routine clinical practice is
expected to grow, boosting market expansion.,” said Mr.
Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Europe Digital PCR
Market By Type (Droplet Digital PCR, Chip-based Digital PCR, Others), By
Product (Instruments, Reagents & Consumables), By Indication (Infectious
Diseases, Oncology, Genetic Disorders, Others), By End User (Hospitals &
Clinics, Pharmaceutical & Biotechnology Industries, Clinical Laboratories,
Academic & Research Organizations), By Country, Competition, Forecast and
Opportunities, 2020-2030F”, has evaluated the future growth potential of Europe
Digital PCR Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Europe Digital PCR Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com